Fig. 2From: SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTsForest plots examining the kidney outcome in participants of ten CVOTs irrespective of the presence of type 2 diabetes and diabetic kidney disease. There is a moderate and borderline significant heterogeneity in the analysis (I2 = 35%, P = 0.10)Back to article page